Trospium chloride: The European experience

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 10, 2006, Pages 1373-1380

  Madersbacher, Helmut ^a   Rovner, Eric ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTROPANE DERIVATIVE; TROSPIUM CHLORIDE;

ADULT; AGED; BLADDER; CHILD; DRUG ANTAGONISM; DRUG EFFECT; EUROPE; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVERACTIVE BLADDER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; ADULT; AGED; CHILD; EUROPE; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NORTROPANES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 36048942612     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.10.1373     Document Type: Review

References (30)

1. ABRAMS P, CARDOZO L, FALL M et al.: The standardization of terminology in lowering urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Urology (2003) 61:37-49. (Pubitemid 36151708)
2. MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THÜROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. (2001) 79:760-766. (Pubitemid 34204313)
3. STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20:327-336.
4. SCHWANTES U, TOPFMEIER P: Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia - chances for improvement of therapy. Int. J. Clin. Pharmacol. Ther. (1999) 37:209-218. • Reviews and highlights some important items for tolerance of anticholinergics.
5. WEIN AJ, ROVNER ES: Pharmacologic management of urinary incontinence in women. Urol. Clin. N. Am. (2002) 29:537-550. • Deals with specific aspects of pharmacotherapy in incontinent women.
6. ANDERSSON KE: Antimuscarinics for treatment of overactive bladder. Lancet (2004) 3:46-53. •• Excellent overview on current state of the art.
7. PIETZKO A, DIMPFEL W, SCHWANTES U, TOPFMEIER P: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur. J. Clin. Pharmacol. (1994) 47:337-343. •• Documents for the first time possible adverse events of anticholinergics on brain function.
8. TODOROVA A, VONDERHEID-GUTH B, DIMPFEL W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. (2001) 41:636-644.
9. DIEFENBACH K, DONATH F, MAURER A et al.: Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin. Drug Invest. (2003) 23:395-404. •• The results of this study combined with those of [30] clearly indicate that the blood-brain barrier may become leaky with age, allowing anticholinergics that normally do not enter the CNS, to pass the blood-brain barrier in the elderly.
10. ALLOUSSI S, LAVAL K-U, ECKERT R et al.: Trospium chloride (Spasmo-lyt®) in patients with motor urge syndrome (detrusor instability): a double-blind, randomized, multicentre, placebo-controlled study. J. Clin. Res. (1998) 1:439-451.
11. FÜSGEN I, HAURI D: Trospium chloride: an effective option for medical treatment of bladder overactivity. Int. J. Clin. Pharmacol. Ther. (2000) 38:223-234.
12. HALASKA M, RALPH G, WIEDEMANN A et al.: Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World. J. Urol. (2003) 20:392-399. • Documents long-term tolerability and efficacy of trospium.
13. HÄFNER K, RETTIG K, MADERSBACHER H: Irritable bladder and urge incontinence: trospium chloride proves successful in elderly. Geriatrie Praxis. (1998) 1-2:54-56.
14. HÖFNER K, OELKE M, MACHTENS S, GRÜNEWALD V: Trospium chloride - an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J. Urol. (2001) 19:336-343. • Comprehensive overview of trospium.
15. STÖHRER M, BAUER P, GIANNETTI BM, RICHTER R, BURGDÖRFER H, MÜRTZ G: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urol. Int. (1991) 47:138-143.
16. MADERSBACHER H: Trospium chloride (Spasmo-lyt® pills) - an effective therapeutic for urge (irritable bladder) syndrome. Result of a use observation study with concomitant treatment on 971 patients. Urologe. (1993) 33:89-93.
17. MADERBACHER H, STÖHRER M, RICHTER R, BURGDÖRFER H, HACHEN HJ, MÜRTZ G: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br. J. Urol. (1995) 75:452-456. • A urodynamically controlled study, it provides head-to-head comparison of trospium versus oxybutynin in neurogenic detrusor overactivity.
18. MADERBACHER H, RETTIG K: Trospium chloride in general practice. Therapeutic experience in treatment of irritable bladder symptoms and urge incontinence. Allgemeinmed. (1997) 73:378-383.
19. FORTH W, HENSCHLER D, RUMMELW, STARKE K: Allgemeine Pharmakologie und Toxikologie [General Pharmacology and Toxicology]. BI-Wissenschaftsverlag, Mannheim, Germany, (1993):128-133.
20. ÜCKERT S, STIEF CG, ODENTHAL KP, TRUSS MC, LIETZ B, JONAS U: Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. Arzneimittel Forschung. (2000) 50:456-460. (Pubitemid 30333576)
21. ZERRES K, ZAIGLER M, RIETBROCK S et al.: Phamacokinetics of single- and multiple-dose trospium chloride in elderly volunteers using a replicative design [abstract no. 687]. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 357(Suppl.):R175.
22. INDEVUS PHARMACEUTICALS, INC: Sanctura™ (trospium chloride) prescribing information. Indevus Pharmaceuticals, Inc.. Lexington, MA (2004).
23. MADAUS AG: Spasmo-lyt® (trospium chloride) prescribing information. Madaus AG. Cologne, Germany (1999).
24. LANGGUTH P, KUBIS A, KRUMBIEGEL G et al.: Intestinal absorption of the quaternary trospium chloride: permeability-lowering factors and bioavailabilities for oral dosage forms. Eur. J. Pharmaceut. Biopharmaceut. (1997) 43:265-272.
25. FRÖHLICH G, BULITTA M, STRÖSSER W: Trospium chloride in patients with detrusor overactivity. Int. J. Clin. Pharmacol. Ther. (2002) 40:1-9. • Describes a possible local anticholinergic effect on the bladder by trospium, which is excreted with urine in high concentrations.
26. CARDOZO L, CHAPPLE CR, TOOZS-HOBSON P et al.: Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. (2000) 85:659-664. (Pubitemid 30192830)
27. WIEDEMANN A, ZUMBE J: Treatment of incontinence in children with trospium chloride. Urologe. (1998) 38:531-534. (Pubitemid 29009814)
28. JÜNEMANN KP, AL-SHUKRI S: Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled multicentre clinical trial. Neurourol. Urodyn. (2000) 19:488-490. • Provides head-to-head comparison of trospium versus tolterodine.
29. JÜNEMANN K-P, FÜSGEN I, TOLSTOVA S: Trospium chloride 40 mg - a placebo-controlled, randomized, double-blind clinical trial on the efficacy and tolerability for 3 weeks in patients with urge-syndrome. Eur. Urol. (2000) 37(Suppl. 2):84. Abstr. 336.
30. DIEFENBACH K, ARNOLD G, WOLLNY A, SCHWANTES U, HASELMANN J, ROOTS I: Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BTU Int. (2005) 95:346-349. •• The results of this study combined with those of [9] clearly indicate that the blood-brain barrier may become leaky with age, allowing anticholinergics that normally do not enter the CNS to pass the blood-brain barrier in the elderly. (Pubitemid 40283121)